Australia's largest stock trading and investment forum Australia's #1 stock forum

CPH

Click for more information

0.00%

0.9¢ creso pharma limited

Ann: Creso Pharma Anticipates Increasing Q4 2021 Swiss Revenue, page-10

First 10 Last

Share
Profile

Follow
surfthemarket

464 Posts.

222

11/11/21

16:01

Post #: 57501003
Share

Originally posted by pierre23: ↑

Unfortunately not many people understand that here. Quarter on quarter, they continue to report increased sales, however their increased costs are up much higher. It's a losing business model to date when a Company can't stop the bleeding (most likely intentionally - see below).

However, as previously established it's in EverBlu Capital and Adam Blumenthals best interest to continue with high costs and expenditure, to need to raise capital and get even richer off the fees.

There's a reason why they call it a "conflict of interest" and the ASX should definitely put safe guards in place to protect shareholder interests when this happens - won't happen though.

Here's hoping they can actually report an increase in revenue while decreasing costs.

Expand

Some rather serious accusations there Peter23.

Have a look at my breakdown of (reduced) costs after the last Quarterly ............ I laid it out as simply as I could for you.

CPH Price at posting: 14.8¢ Sentiment: Buy Disclosure: Held
2 Upvote

1 Great analysis

Reply

Top Stories

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

There are more pages in this discussion • 60 more messages in this thread...

First 10 Last

Add CPH (ASX) to my watchlist